Ann: Dronabinol Supply Agreement/Sleep Apnoea Trial Update, page-20

@moguns, good to have a new poster and investor on the threads. As a BOT shareholder you would be aware that they use a synthetic CBD product. A synthetic product is useful because of the ease of producing a pharmaceutical grade product in scaleable quantities.

Likewise, IHL are using Dronabinol which is a synthetic THC and which will form part of their “unique” formula for treating obstructive sleep apnea. Presumably the company will be “coy” about the other ingredients that constitute the final recipe.

As to your question on exclusivity this delves into the realms of patent protection and BOT is targeting the same options as IHL. Firstly IHL will look to patent a “unique” “novel” product whose main ingredient is Dronabinol for the treatment of OSA. And perhaps even more importantly they will probably seek to register the product with the Therapeutics Goods Act (TGA). New products registered under the act are granted a 5 year exclusivity. This is potentially of greater value than a patent as it blocks a potential competitor from entering the market for a period of time.

In other words, being first to market (or register) is a massive advantage. By the way, if you talk to the BOT MD he will tell you this is the same path they are following.

Exciting stuff. BOT now $160 million and IHL $25 million.